Long Ideas - We last covered Synageva BioPharma (GEVA) in early January, arguing that the company faced fundamental risks that made its valuation a concern moving forward. But … Continue Reading
Read nowMost Popular - A study published yesterday in PLOS Biology offers a damning assessment of recent IPO PTC Therapeutics’ (PTCT) lead candidate ataluren. PTC began trading on the Nasdaq last … Continue Reading
Read nowMost Popular - Isis Pharmaceuticals (ISIS) revealed impressive numbers from its Phase II trial of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes yesterday at the American Diabetes Association … Continue Reading
Read nowLong Ideas - Amarin (AMRN) announced Friday morning that a Phase I trial comparing the bioavailability of components from a fixed-dose combination of Vascepa plus rosuvastatin, to concomitant … Continue Reading
Read nowLong Ideas - Shares of Medivation (MDVN) fell sharply on Monday June 17, closing down over 6% on news that Johnson & Johnson (JNJ) has acquired Aragon Pharmaceuticals … Continue Reading
Read nowLong Ideas - As one of the premier medical conferences globally, the annual meeting of the American Society for Clinical Oncology has the potential to create or destroy … Continue Reading
Read nowLong Ideas - BioMarin (BMRN) took a beating on Monday as more mature data at the American Society for Clinical Oncology meeting for its Phase I PARP inhibitor, … Continue Reading
Read now